Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
MEDP - Medpace Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$646.90
DETAILS
HIGH:
$730.00
LOW:
$515.00
MEDIAN:
$672.50
CONSENSUS:
$646.90
DOWNSIDE:
4.41%
Stock News
All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy
Medpace (MEDP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here's Why Medpace (MEDP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate
Medpace Holdings is downgraded from "Buy" to "Hold" due to decelerating growth metrics and underwhelming forward guidance. Q3 2026 Net New Business Awards rose just 10.6%, a sharp slowdown from Q2's 28.2% growth, signaling weaker contract momentum. Revenue growth in Q3 2026 was 8.5% to $716M, below the prior quarter's 17.2% pace and only modestly above consensus.
Medpace: 3 Key Takeaways for Long-Term Investors
Net new business awards reached $873 million in the third quarter. Ending backlog reached $3.2 billion, up 5.6% year over year.
Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcript
Medpace Holdings, Inc. ( MEDP ) Q3 2026 Earnings Call October 22, 2026 9:00 AM EDT Company Participants David Ruhe - Associate Director of Financial Planning & Analysis August Troendle - CEO, President & Chairman Kevin Brady - CFO & Treasurer Conference Call Participants Michael Cherny - Leerink Partners LLC, Research Division Jailendra Singh - Truist Securities, Inc., Research Division Tucker Remmers - UBS Investment Bank, Research Division Ann Hynes - Mizuho Securities USA LLC, Research Division Justin Bowers - Deutsche Bank AG, Research Division Ryan Halsted - RBC Capital Markets, Research Division David Windley - Jefferies LLC, Research Division Christine Rains - William Blair & Company L.L.C., Research Division Eric Coldwell - Robert W.
Medpace Q3 Earnings Call Highlights
Medpace NASDAQ: MEDP reported third-quarter 2026 revenue growth of 8.5% and record net new business awards, while management said the clinical research organization continues to see a strong operating environment marked by healthy request-for-proposal activity, initial award notifications and win rates.
Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates
Medpace (MEDP) came out with quarterly earnings of $4.84 per share, beating the Zacks Consensus Estimate of $4.45 per share. This compares to earnings of $3.86 per share a year ago.
A Look at Medpace Holdings Inc (MEDP) After 6.4% Gain -- GF Value $539.19 vs Price $662.48
On October 21, 2026, Medpace Holdings Inc (MEDP) shares rose 6.4% to $662.48, continuing a strong upward trend that has seen the stock increase 21.4% over the p
Medpace Slips Despite Third-Quarter Beat, Solid Earnings Outlook
Medpace stock slipped late Wednesday despite beating third-quarter forecasts and issuing an above-Street view for 2026 earnings.
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025. Backlog as of September 30.
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One
Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer against potential cash flow volatility as biotech funding rebounds.
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.
Medpace Holdings, Inc. $MEDP Stock Holdings Decreased by Argent Capital Management LLC
Argent Capital Management LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ: MEDP) by 5.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 56,996 shares of the company's stock after selling 3,218 shares during the period. Medpace accounts for approximately 0.3% of Argent Capital
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.
CON or MEDP: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Envestnet Asset Management Inc. Cuts Position in Medpace Holdings, Inc. $MEDP
Envestnet Asset Management Inc. lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) by 30.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,802 shares of the company's stock after selling 40,222 shares during the period. Envestnet Asset Management
Medpace (NASDAQ:MEDP) CEO August Troendle Sells 21,883 Shares
Medpace Holdings, Inc. (NASDAQ: MEDP - Get Free Report) CEO August Troendle sold 21,883 shares of the business's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $623.29, for a total value of $13,639,455.07. Following the completion of the transaction, the chief executive officer directly owned 482,390 shares
Price Targets
Medpace price target raised to $670 from $600 at BMO Capital
$670.00
(was $668.97)
BMO Capital
Medpace price target raised to $633 from $609 at Truist
$633.00
(was $656.25)
Jailendra Singh
·
Truist Financial
Medpace price target raised to $700 from $673 at UBS
$700.00
(was $662.60)
UBS
Medpace price target raised to $730 from $700 at Mizuho
$730.00
(was $653.96)
Mizuho Securities
Medpace price target raised to $699 from $638 at Baird
$699.00
(was $653.96)
Robert W. Baird
Medpace price target raised to $675 from $625 at Barclays
$675.00
(was $653.96)
Barclays
Medpace price target raised to $700 from $665 at Mizuho
$700.00
(was $602.90)
Mizuho Securities
Medpace price target raised to $625 from $600 at Barclays
$625.00
(was $602.90)
Barclays
Medpace resumed with a Neutral at UBS
$673.00
(was $622.11)
UBS
Medpace price target raised to $692 from $484 at RBC Capital
$692.00
(was $601.73)
Ryan Halsted
·
RBC Capital
Medpace price target raised to $665 from $586 at Mizuho
$665.00
(was $605.82)
Mizuho Securities
Medpace price target raised to $600 from $400 at BMO Capital
$600.00
(was $605.82)
BMO Capital
Medpace price target raised to $624 from $547 at Baird
$624.00
(was $605.82)
Robert W. Baird
Medpace price target raised to $600 from $450 at Barclays
$600.00
(was $605.82)
Luke Sergott
·
Barclays
Medpace price target raised to $620 from $515 at Leerink
$620.00
(was $605.82)
Leerink Partners
Medpace price target raised to $535 from $480 at Deutsche Bank
$535.00
(was $603.00)
Deutsche Bank
Medpace price target raised to $586 from $495 at Mizuho
$586.00
(was $538.23)
Mizuho Securities
Medpace downgraded to Neutral from Outperform at Baird
$547.00
(was $546.29)
Eric Coldwell
·
Robert W. Baird
Jefferies Downgrades Medpace (MEDP) to Hold
$515.00
(was $565.09)
David Windley
·
Jefferies
Medpace price target lowered to $400 from $460 at BMO Capital
$400.00
(was $402.81)
BMO Capital